Hib-DTaP vaccine - sanofi pasteur

Drug Profile

Hib-DTaP vaccine - sanofi pasteur

Alternative Names: Hib-DTP-acellular vaccine - sanofi pasteur; TriHIBit

Latest Information Update: 19 Jan 2005

Price : $50

At a glance

  • Originator sanofi pasteur
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Tetanus

Most Recent Events

  • 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top